Literature DB >> 17584046

Testosterone and cardioprotection against myocardial ischemia.

Sharon Tsang1, Jing Liu, Tak Ming Wong.   

Abstract

Male gender is a risk factor for cardiovascular diseases. Testosterone being the main male sex hormone is therefore believed to be responsible for the deleterious effect of the male. However, there are recent studies showing that testosterone level is lower in patients with ischemic heart diseases, and testosterone treatment alleviates the symptoms. Earlier studies showed that functional androgen receptors are present in the heart and that testosterone acts directly at the myocardium. There is increasing evidence to suggest testosterone confers cardioprotection by direct action on the myocardium. Here, we review the recent literature on association between testosterone and myocardial ischemia in males, and the signal transduction mechanisms that mediate the action of testosterone in the heart. The studies reviewed in this article provide evidence that testosterone may confer protection via a varieties of mechanisms, which may be both genomic and non-genomic. Further studies are warranted to further delineate the integration of signaling mechanisms and to explore the possibility of using testosterone in the aging male population with ischemic heart diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17584046     DOI: 10.2174/187152907780830888

Source DB:  PubMed          Journal:  Cardiovasc Hematol Disord Drug Targets        ISSN: 1871-529X


  9 in total

Review 1.  Myocardial AKT: the omnipresent nexus.

Authors:  Mark A Sussman; Mirko Völkers; Kimberlee Fischer; Brandi Bailey; Christopher T Cottage; Shabana Din; Natalie Gude; Daniele Avitabile; Roberto Alvarez; Balaji Sundararaman; Pearl Quijada; Matt Mason; Mathias H Konstandin; Amy Malhowski; Zhaokang Cheng; Mohsin Khan; Michael McGregor
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

2.  Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.

Authors:  Elisa Martín-Merino; Saga Johansson; Thomas Morris; Luis A García Rodríguez
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

3.  Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer.

Authors:  Theodoros Karantanos; Styliani Karanika
Journal:  Ann Transl Med       Date:  2016-03

4.  Isoflurane preconditioning neuroprotection in experimental focal stroke is androgen-dependent in male mice.

Authors:  W Zhu; L Wang; L Zhang; J M Palmateer; N L Libal; P D Hurn; P S Herson; S J Murphy
Journal:  Neuroscience       Date:  2010-05-24       Impact factor: 3.590

5.  Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation.

Authors:  S Tsang; S Wu; J Liu; T M Wong
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

6.  Polymorphisms of steroid 5-alpha-reductase type I (SRD5A1) gene are associated to peripheral arterial disease.

Authors:  S S Signorelli; V Barresi; N Musso; M Anzaldi; E Croce; V Fiore; D F Condorelli
Journal:  J Endocrinol Invest       Date:  2008-12       Impact factor: 4.256

7.  Chronic testosterone replacement exerts cardioprotection against cardiac ischemia-reperfusion injury by attenuating mitochondrial dysfunction in testosterone-deprived rats.

Authors:  Wanpitak Pongkan; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

Review 8.  An emerging perspective on sex differences: Intersecting S-nitrosothiol and aldehyde signaling in the heart.

Authors:  Kevin M Casin; Mark J Kohr
Journal:  Redox Biol       Date:  2020-01-25       Impact factor: 11.799

9.  Testosterone protects female embryonic heart H9c2 cells against severe metabolic stress by activating estrogen receptors and up-regulating IES SUR2B.

Authors:  Thomas Ballantyne; Qingyou Du; Sofija Jovanović; Andrew Neemo; Robert Holmes; Sharabh Sinha; Aleksandar Jovanović
Journal:  Int J Biochem Cell Biol       Date:  2012-10-22       Impact factor: 5.085

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.